Recently, a variant in the extracellular domain of Notch 1 that provides a growth advantage to cells and confirms the suitability of the Notch pathway as a second-line druggable target was found in a severe form of lymphoma—the anaplastic large cell lymphoma [91]. The gene discussed is NOTCH1; the disease is lymphoma.